Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for Immunocore in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings of ($2.33) per share for the year. The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share.
IMCR has been the topic of a number of other reports. Morgan Stanley restated an "equal weight" rating and set a $35.00 price objective (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a research report on Friday, January 10th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and reduced their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, Guggenheim lowered Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $65.64.
Read Our Latest Stock Analysis on Immunocore
Immunocore Stock Performance
Shares of IMCR traded up $0.77 on Wednesday, reaching $30.77. 167,510 shares of the stock traded hands, compared to its average volume of 272,656. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -32.36 and a beta of 0.76. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 12 month low of $27.69 and a 12 month high of $76.98. The stock's 50-day moving average price is $30.56 and its 200-day moving average price is $33.45.
Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analysts' expectations of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore's quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.59) earnings per share.
Institutional Trading of Immunocore
Hedge funds have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its stake in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after acquiring an additional 1,461 shares during the period. Connective Portfolio Management LLC bought a new position in shares of Immunocore in the 3rd quarter valued at $218,000. China Universal Asset Management Co. Ltd. grew its position in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after acquiring an additional 3,053 shares during the last quarter. XTX Topco Ltd bought a new stake in Immunocore during the 2nd quarter worth $303,000. Finally, GSA Capital Partners LLP bought a new stake in Immunocore during the 3rd quarter worth $406,000. 84.50% of the stock is owned by institutional investors and hedge funds.
About Immunocore
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
